Skip to main content
Premium Trial:

Request an Annual Quote

Jonathan Rowe, David Lieberman, David Sidransky, Richard Wender, Richard Lussier, Ignacio Martinez, Duncan Whitney

Premium
Jonathan Rowe will take over the role of senior VP of strategy and clinical innovation at Gene Express, the company said last week.
 
Rowe has worked at Pfizer as a senior director of worldwide pharmaceutical sciences, director of intellectual property strategy management, and clinical director of the cardiovascular risk factors group.
 
Rowe has also served as a scientific advisor for the law firm Kaye, Scholer, where he was involved in IP litigation for biotechnology and pharmaceutical firms.
 

 
GeneNews has appointed three new members to its Colorectal Cancer Clinical Advisory Board: David Lieberman, David Sidransky, and Richard Wender.
 
Lieberman is a professor of medicine and chief of gastroenterology at Oregon Health Sciences University and the Portland Veterans Affairs Medical Center. In 2007 he received the Laurel for Leadership from the Cancer Research and Prevention Foundation.
 
Sidransky is a director of the head and neck cancer research program at the Sidney Kimmel Comprehensive Cancer Center, as well as a professor of oncology, cellular and molecular medicine and genetics, and other specialties at the Johns Hopkins University School of Medicine. He received the 2004 Hinda Rosenthal Award from the American Association of Cancer Research.
 
Wender is chair of the department of family and community medicine at Thomas Jefferson University in Philadelphia and he has served on the steering committee of the National Colorectal Cancer Roundtable and worked with the US Centers for Disease Control and Prevention to develop a training program aimed at colorectal cancer prevention and screening.
 

 
Progenika Biopharma announced this week that it has named Richard Lussier as its chief operating officer and general manager; Ignacio Martinez as its chief financial officer; and Duncan Whitney as its chief scientific officer.
 
Prior to joining Progenika, Lussier spent more than 13 years at Applera, where he held several technical, marketing, and management roles with Applied Biosystems and Celera Genomics. Lussier was most recently at Solexa, which was acquired by Illumina in January 2007.
 
Martinez joined Progenika in 2005 as the company’s chief financial officer in Spain, and then relocated to Boston as a member of the executive team to set up the company’s US subsidiary. Formerly, Martinez held positions at Seed Capital and Najeti Capital in Spain.
 
Whitney comes to Progenika from US Genomics, where he was the VP of research and development.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.